In our current study, we investigated the functional role of the Ras/MAPK cascade in regulating K-Ras wild-type CCA development and evaluated the therapeutic potential of a MEK inhibitor, either alone or in combination with an AKT/mTOR inhibitor, for CCA treatment. This evidence concerns the gene MTOR and cholangiocarcinoma.